Latest News

February 7, 2023

IR “Third Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2023 [Material, Webcast]”

February 6, 2023

IR “Third Quarter Financial Report for the Fiscal Year Ending March 31, 2023”

January 27, 2023

Sustainability "Trusting Relationships with Partners Hold the Key to NTDs Therapeutic Drug Development ー Mr. Tatsuro Kuzuki, DNDi Japan"

January 20, 2023

Sustainability "Visualization of Non-Financial Capital:
Impact-Weighted Accounting of Free Provision of diethylcarbamazine (DEC) Tablets"

January 10, 2023

Eisai Media/Investor Conference: Eisai’s Approach to U.S. Pricing for LEQEMBI™ (lecanemab), a Treatment for Early Alzheimer’s Disease (Video)

December 29, 2022

Sustainability "Collaborative Project with AAR Japan to Tackle Mycetoma in SudanーOnline Trainings for Local Cooperative Organizations and Healthcare Professionals through Multi-sectoral Partnerships"

December 28, 2022

Sustainability "Call for Japanese Government’s Continued Support for Elimination of Neglected Tropical DiseasesーEisai’s Vice President Participated in a Seminar Hosted by DNDi and GHIT Fund for Japanese Parliamentarians"

December 28, 2022

Recent hhc Activities “Promoting Global Knowledge Exchange through 'hhc Initiative 2022'”

December 16, 2022

About Eisai “Corporate Governance Report Notice”

November 30, 2022

Wednesday, November 30, 2022 09:50 a.m.- (JST)
Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 [Material]